The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study

Introduction: Coronavirus disease 2019 (COVID-19) still has a high mortality rate when it is severe. Regdanvimab (CT-P59), a neutralizing monoclonal antibody that has been proven effective against mild to moderate COVID-19, may be effective against severe COVID-19. This study was conducted to determ...

Descripción completa

Detalles Bibliográficos
Autores principales: Chae, Ganghee, Choi, Aram, Lim, Soyeoun, Park, Sooneun, Lee, Seungjun, Ahn, Youngick, Kim, Jinhyoung, Ra, Seungwon, Jegal, Yangjin, Ahn, Jongjoon, Park, Eunji, Jun, Jaebum, Kwon, Woonjung, Lee, Taehoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950958/
https://www.ncbi.nlm.nih.gov/pubmed/35324598
http://dx.doi.org/10.3390/tropicalmed7030051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950958/
https://www.ncbi.nlm.nih.gov/pubmed/35324598
http://dx.doi.org/10.3390/tropicalmed7030051

Ejemplares similares